FDA Lifts Curtain On Homeopathics Regulatory Evaluation With Public Hearing
This article was originally published in The Tan Sheet
Executive Summary
FDA’s public hearing announcement comes a week after it alerted consumers to the prevalence of homeopathics with violative indications for treating asthma and could signal the start of the separate review of homeopathic regulations the agency said it would undertake when the OTC drug review began in 1972.